The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded. [Operator instructions] I would now like to turn the call over to Mr. Peter ...

Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

The decision to terminate the HYPERION trial reflects a loss of clinical equipoise, making it unethical to continue the placebo-controlled study.

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...